Santarus to Host Investor and Analyst Day on April 11, 2013
SAN DIEGO, CA -- (Marketwire) -- 03/26/13 -- Santarus, Inc. (NASDAQ:
SNTS) will hold an Investor and Analyst Day on Thursday, April 11,
2013 from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at
the Millennium Broadway Hotel, 145 West 44th Street, New York City.
President and chief executive officer, Gerald T. Proehl, and other
members of the senior management team will present an overview of the
company's growth strategy, current commercial products and
development pipeline to analysts and investors. In addition, a key
opinion leader in gastroenterology will share his thoughts on
ulcerative colitis and therapeutic perspectives. This event will be
webcast live on Santarus' website at www.santarus.com beginning at
9:00 a.m. EDT. An archive of the webcast will be available shortly
after conclusion of the event and can be viewed at the same link.
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on five products.
UCERIS(TM) (budesonide) extended release tablets for the induction of
remission in patients with active, mild to moderate ulcerative
colitis and ZEGERID(R) (omeprazole/sodium bicarbonate) for the
treatment of certain upper gastrointestinal disorders are promoted to
gastroenterologists. GLUMETZA(R) (metformin hydrochloride extended
release tablets) and CYCLOSET(R) (bromocriptine mesylate) tablets,
which are indicated as adjuncts to diet and exercise to improve
glycemic control in adults with type 2 diabetes, and FENOGLIDE(R)
(fenofibrate) tablets, which is indicated as an adjunct to diet to
reduce high cholesterol, are promoted to endocrinologists and other
physicians who treat patients with type 2 diabetes. Full prescribing
and safety information for Santarus' products are available at
Santarus' product development pipeline includes the investigational
drug RUCONEST(R) (recombinant human C1 esterase inhibitor) for
treatment of acute attacks of hereditary angioedema. The company
expects to submit a biologics license application (BLA) to the U.S.
od and Drug Administration for RUCONEST in the second quarter of
2013. Santarus is also developing rifamycin SV MMX(R), which is in
Phase III clinical testing for treatment of travelers' diarrhea. In
addition, the company has completed a Phase I clinical program with
SAN-300, an investigational monoclonal antibody. More information
about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should not be
regarded as a representation by Santarus that any of its plans or
objectives will be achieved. Actual results may differ materially
from those set forth in this release due to the risks and
uncertainties inherent in Santarus' business, including, without
limitation: unexpected adverse side effects or inadequate therapeutic
efficacy of Santarus' products and product candidates; the scope and
validity of patent protection for Santarus' products and product
candidates; and other difficulties or delays relating to the
development, testing, manufacturing and marketing of, and obtaining
and maintaining regulatory approvals for, Santarus' products and
product candidates; and other risks detailed in Santarus' prior press
releases as well as in prior public periodic filings with the
Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement and Santarus undertakes no obligation to
revise or update this news release to reflect events or circumstances
after the date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Santarus(R), FENOGLIDE(R), UCERIS(TM) and ZEGERID(R) are trademarks
of Santarus, Inc. GLUMETZA(R) is a trademark of Biovail Laboratories
International S.r.l. licensed exclusively in the United States to
Depomed, Inc. CYCLOSET(R) is a trademark of VeroScience LLC. MMX(R)
is a trademark of Cosmo Technologies Limited.
RUCONEST(R) is a
trademark of Pharming Group N.V.
Martha L. Hough
VP Finance & Investor Relations
Debra P. Crawford
Chief Financial Officer
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Press spacebar to pause and continue. Press esc to stop.